Showing 8101-8110 of 19309 results for "".
The LEVEL UP Trial: Comparing Atopic Dermatitis Treatments
https://reachmd.com/programs/clinicians-roundtable/the-level-up-trial-comparing-atopic-dermatitis-treatments/27070/Explore a recent trial examining the efficacy of upadacitinib and dupilumab in atopic dermatitis patients.Ditch the PowerPoint Slides: You Are the Message
https://reachmd.com/programs/speaking-of/ditch-powerpoint-slides-you-are-message/10111/YOU are the message, not your slides. Learn how to properly use slides when giving a presentation.Pediatric Metabolic Syndrome
https://reachmd.com/programs/lipid-luminations/pediatric-metabolic-syndrome/4545/A series of well-established risk factors define the metabolic syndrome in adults. The situation is less clear for our younger patients, as they typically do not develop cardiovascular disease or experience cardiac events. The key for kids, it seems, is to determine their risk for disease in adulthoNeural Network Models of Depression
https://reachmd.com/programs/clinicians-roundtable/neural-network-models-of-depression/3837/Dr. Helen Mayberg, professor of psychiatry and neurology at Emory University School of Medicine, joins host Dr. Cathleen Margolin to discuss neural network models of depression. Sharing more than two decades of work in this area, Dr. Mayberg explains how models of mood regulation have led to the devIs there a critical window to begin Hormone Replacement Therapy? Does it really exist?
https://reachmd.com/programs/advances-in-womens-health/is-there-a-critical-window-to-begin-hormone-replacement-therapy-does-it-really-exist/3162/During the 1990's multiple studies suggested hormone replacement therapy would decrease heart disease in women and prolong life. Many doctors encouraged their patients to take estrogen even if they didn't have menopausal symptoms. Dr. Veronica Ravnikar discusses optimizing cardiovascular and cognideCode MI: Another Tool to Assess Patient's MI Risk
https://reachmd.com/programs/clinicians-roundtable/decode-mi-another-tool-to-assess-patients-mi-risk/3291/Are we already able to assess our patients accurately for MI risk factors or is there another test that could provide more accuracy? Our guest today, Dr. Jeffrey Gulcher, chief scientific officer and co-founder of deCode Genetics tells host, Dr. Larry Kaskel about deCode MI. Learn how toUnderstanding Vutrisiran’s Cardiac Effects in HELIOS-B
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/understanding-vutrisirans-cardiac-effects-in-helios-b/49038/The HELIOS-B trial found that vutrisiran therapy caused significant reductions in mortality and cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). In this episode, Dr. Karola Jering joins Dr. Steve Jackson to discuss a secondary analysis of HELIOS-B, which furtherAddressing Diagnostic Gaps in Psoriasis for Skin of Color
https://reachmd.com/programs/dermconsult/addressing-diagnostic-gaps-in-psoriasis-for-skin-of-color/39686/Because psoriasis presents differently in patients with different skin colors, psoriasis patients with skin of color may experience misdiagnoses, delays, and undertreatment. Tune in to hear Dr. Megan Hauptman, Clinical Research Fellow in the Program for Clinical Research in Dermatology at the UniverCosibelimab Delivers Durable Responses in Advanced CSCC
https://reachmd.com/programs/project-oncology/cosibelimab-delivers-durable-responses-in-advanced-cscc/54699/The Next Chapter: SABCS 2025 and the Future of HR+ HER2− Breast Cancer Care
https://reachmd.com/programs/project-oncology/sabcs-2025-future-of-hr-her2-breast-cancer-care/36166/The 2025 San Antonio Breast Cancer Symposium (SABCS) brought forward key advances shaping the future of hormone receptor-positive, HER2-negative (HR+ HER−) advanced breast cancer care. From novel trial designs to emerging resistance pathways and supportive care considerations, new data are helping r